Atreca Inc. (BCEL) July Data Could Lead to a Positive Surprise - Jefferies

Jefferies analyst Roger Song reiterated a Buy rating and $30.00 price target on Atreca Inc. (NASDAQ: BCEL) noting the company will report will report preliminary first-in-human Ph1 ATRC-101 dose escalation data in solid tumors.

The analyst stated "While data will likely be preliminary, we believe it could be stock moving (~50-100%+ up / ~30-50% down) given novel MOA, large market opportunity, platform read through and low EV. Based on our investor interactions, we see expectation quite low, and bar for initial read being limited RECIST response(s) and/or prolong stable disease, clean safety, and supportive biomarker." "We have received a fair number of inbounds regarding the upcoming data readout, and see the consensus leans towards low expectation - potential for a positive surprise."

For an analyst ratings summary and ratings history on Atreca Inc. click here. For more ratings news on Atreca Inc. click here.

Shares of Atreca Inc. closed at $8.52 yesterday.

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• Adeia (ADEA) PT Raised to $50 at BWS Financial
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy